Cellares, a cell therapy manufacturing specialist, announced plans to lay off 100 employees after an unnamed large pharmaceutical customer terminated a contract, according to CEO Fabian Gerlinghaus. The restructuring underscores volatility in capacity planning for CDMO-leaning cell therapy manufacturers, particularly as sponsors reassess timelines and make contract changes. The move may accelerate consolidation pressures across the cell therapy manufacturing supply chain while highlighting how quickly staffing and throughput strategies can change when commercial commitments shift.